BACKGROUND & AIMS:
Etrolizumab is a humanized monoclonal antibody against the b7 integrin subunit that has shown efficacy vs placebo in patients with moderate to severely active ulcerative colitis (UC). Patients with colon tissues that expressed high levels of the integrin aE gene (ITGAE) appeared to have the best response. We compared differences in colonic expression of ITGAE and other genes between patients who achieved clinical remission with etrolizumab vs those who did.
METHODS:
We performed a retrospective analysis of data collected from 110 patients with UC who participated in a phase 2 placebo-controlled trial of etrolizumab, as well as from 21 patients with UC or without inflammatory bowel disease (controls) enrolled in an observational study at a separate site. Colon biopsies were collected from patients in both studies and analyzed by immunohistochemistry and gene expression profiling. Mononuclear cells were isolated and analyzed by flow cytometry. We identified biomarkers associated with response to etrolizumab. In the placebo-controlled trial, clinical remission was defined as total Mayo Clinic Score 2, with no individual subscore >1, and mucosal healing was defined as endoscopic score 1. RESULTS: Colon tissues collected at baseline from patients who had a clinical response to etrolizumab expressed higher levels of T-cellÀassociated genes than patients who did not respond (P < .05). Colonic CD4 þ integrin aE þ cells from patients with UC expressed higher levels of granzyme A messenger RNA (GZMA mRNA) than CD4 þ aE À cells (P < .0001); granzyme A and integrin aE protein were detected in the same cells. Of patients receiving 100 mg etrolizumab, a higher proportion of those with high levels of GZMA mRNA (41%) or ITGAE mRNA (38%) than those with low levels of GZMA (6%) or ITGAE mRNA (13%) achieved clinical remission (P < .05) and mucosal healing (41% GZMA high vs 19% GZMA low and 44% ITGAE high vs 19% ITGAE low ). Compared with ITGAE low and GZMA low patients, patients with ITGAE high and GZMA high had higher baseline numbers of epithelial cryptassociated integrin aE þ cells (P < .01 for both), but a smaller number of crypt-associated integrin aE þ cells after etrolizumab treatment (P < .05 for both). After 10 weeks of etrolizumab treatment, expression of genes associated with T-cell activation and genes encoding inflammatory cytokines decreased by 40%À80% from baseline (P < .05) in patients with colon tissues expressing high levels of GZMA at baseline. CONCLUSIONS: Levels of GZMA and ITGAE mRNAs in colon tissues can identify patients with UC who are most likely to benefit from etrolizumab; expression levels decrease with etrolizumab administration in biomarker high patients. Larger, prospective studies of markers are needed to assess their clinical value.
Keywords: IBD Drug; Response to Therapy; Anti-Integrin; Personalized Medicine. U lcerative colitis (UC) is a chronic inflammatory disease of the colon. Current therapies, such as corticosteroids, immunosuppressants, and anti-tumor necrosis factor (TNF) antibodies, are not universally effective at induction and maintenance of remission, 1 with z25% of patients requiring colectomy. 2 This variable response to treatment and disease progression may reflect significant heterogeneity in disease pathobiology. 3, 4 Improved stratification driven by patient heterogeneity may help guide choice of therapeutic intervention and enhance efficacy and safety.
The integrin-dependent migration and retention of leukocytes to the gut plays an important role in the pathogenesis of inflammatory bowel disease (IBD). 5, 6 Subsets of immune cells, including B cells, naïve and gut homing T cells, natural killer (NK) cells, dendritic cells, stimulated macrophages, monocytes, and eosinophils 7 express a4b7 to mediate binding to mucosal addressin cell adhesion molecule 1 (MAd-CAM-1) on high endothelial venules of Peyer's patches, mesenteric lymph nodes, and postcapillary venules of gut lamina propria (LP). 8 Interaction of a4b7 with MAdCAM-1 mediates the extravasation of naïve and activated leukocytes from blood to gut-associated lymphoid tissues and the LP. Increased MAdCAM-1 expression has been reported in active UC. 8, 9 Recent studies that show induction of clinical remission in UC patients after immunoblockade of leukocyte trafficking support the importance of leukocyte homing in disease pathobiology.
10À12
b7 integrin can also heterodimerize with aE integrin to mediate binding to E-cadherin expressed on epithelial cells. The aEb7 integrin is expressed on subsets of T cells, dendritic cells, mast cells, 7 innate lymphoid cells, 13 and tumorinfiltrating NK cells.
14 Within the gut, the interaction between aEb7 and E-cadherin enables retention of lymphocytes in the intraepithelial compartment. More than 90% of intraepithelial lymphocytes (IELs) and a minority of LP lymphocytes express aEb7. 15 The proportion of mucosal T cells that express aE was higher in intestinal tissues compared with other organs, such as the lungs and spleen. 16 aE expression has been shown to enhance IEL activation, 17 promote antitumor cytotoxicity of T lymphocytes, 18, 19 and modulate cell motility. 20 The understanding of the role of aEb7 integrin in both IEL and LP cells in the gut is evolving. In murine studies, IELs can act as effector memory T cells to protect the epithelium from pathogens. 21 There is emerging evidence that aEb7 þ cells may play a pathogenic role in the gut, and aberrant activation of aEb7 þ cells may contribute to inflammation and pathobiology of UC (unpublished data, 2014). aEb7 þ memory CD8 þ T cells with the capacity to produce proinflammatory cytokines are highly enriched in the gut compared with other tissues. 16, 22 aE þ CD4 þ and CD8 þ T cells from UC patients, but not control subjects, have an effector phenotype with increased expression of proinflammatory cytokines compared with controls (unpublished data, 2014). aE þ cells from the gut also have high levels of perforin and granzyme A. 23 aE þ intraepithelial type 1 innate lymphoid cells were also found to be increased in patients with Crohn's disease and contribute to the inflammatory process in anti-CD40Àinduced murine colitis. 13 Consistent with this, anti-aE treatment has been shown to attenuate experimental colitis in mice. 24 Etrolizumab, a humanized monoclonal antibody against the b7 integrin subunit, blocks both a4b7:MAdCAM-1 and aEb7:E-cadherin interactions to reduce homing of leukocytes to the gut mucosa and retention of lymphocytes in the intraepithelial compartment, respectively. A recent phase 2 study of etrolizumab demonstrated efficacy relative to placebo in patients with moderate to severely active UC. Subsequent analyses of these data indicated that patients with high aE gene expression or aE þ cell numbers in baseline colonic biopsies might have increased benefit. 11 In the current study, we evaluated baseline differences in colonic gene expression between patients who achieved clinical remission with etrolizumab in the phase 2 study compared with those who did not to identify additional predictive biomarkers of response. The relationship of these genes with etrolizumab therapeutic efficacy was then evaluated.
Materials and Methods

Patient Cohorts
Two independent cohorts of patients were included in this analysis: (1) UC patients enrolled in the phase 2 randomized double-blind placebo-controlled trial of etrolizumab 11 (referred to as cohort 1) and (2) UC patients and non-IBD controls concurrently enrolled in an observational study at a separate site not involved in the phase 2 study (referred to as cohort 2) (unpublished data, 2014). Predictive biomarkers of response to etrolizumab were identified in cohort 1, and gene expression in flow cytometryÀsorted T cells was evaluated in cohort 2. In cohort 1, clinical remission was defined as total Mayo Clinic Score 25 2, with no individual subscore >1, and mucosal healing was defined as endoscopic score 1.
Biopsy Collection
Colonic biopsies were collected from patients in cohort 1 during flexible sigmoidoscopy or full colonoscopy at screening, week 6, and week 10.
11 Biopsies were taken from the most inflamed area of the colon within 10 to 40 cm of the anal verge (avoiding necrotic areas) and placed into RNAlater (Life Technologies, Carlsbad, CA) or formalin.
In cohort 2, colonic biopsies were taken from inflamed and/ or uninflamed areas of the colon and placed into RNAlater, formalin, or processed immediately for cell sorting.
RNA Isolation and Sequencing
RNAlater biopsies were homogenized using Tissuelyzer and RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's instructions. RNA integrity was assessed using the Agilent RNA 6000 Pico Kit on Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA) and quantitated using the Invitrogen Quant-iT RNA Assay Kit (Life Technologies) or NanoDrop (Thermo Scientific, Waltham, MA).
Total RNA (RNA integrity number >5; 250 ng) was put into the Illumina TruSeq RNA Sample Preparation Kit v2 protocol and run in conjunction with Biomek liquid handling platforms (Beckman Coulter Life Sciences, Brea, CA). RNA libraries were evaluated using the Agilent 2200 TapeStation HighSensitivity D1K Tape and quantitative polymerase chain reaction (qPCR) with the KAPA Library Quantification Kit for Illumina sequencing. Then 2 nM of library (12 samples per lane) was loaded for cluster generation and sequenced on the Illumina HiSeq 2000 Sequencing System at 2 Â 50 base pairs read length plus index read. Reads that passed quality filters were determined, and fastq files were generated by Illumina CASAVA v1.8.
Identification of Differentially Expressed Genes
Processing and analysis of the RNA sequencing data were performed using the R programming language (http://www.rproject.org) along with packages from the Bioconductor project (http://bioconductor.org). Raw RNA sequencing reads were processed using the HTSeqGenie Bioconductor package. Reads were aligned to the reference human genome sequence (National Center for Biotechnology Information build 37) using the Genomic Short-Read Nucleotide Alignment Program algorithm. 26 Uniquely aligned read pairs that fell within exons were counted to estimate individual gene expression levels. For inclusion, genes were required to have >10 reads in !4 samples.
Two approaches were taken to identify differentially expressed genes in etrolizumab-treated patients: (1) identification of individual genes associated with clinical remission in response to etrolizumab and (2) gene-set enrichment using predefined groups of immune cell genes derived from comparisons of sorted immune cells defined by Abbas et al 27 (Supplementary Table 1 ).
To calculate differential expression, we used the DESeq2 Bioconductor package 28 that fits a negative binomial generalized linear model to determine the log-fold change and P value for differences between groups. The default library size estimation method was used to account for differences in sequencing depth. The response variable was clinical remission at the primary endpoint of the study. 11 Technical aspects of the sequencing runs and the endoscopic subscore at the screening visit were also incorporated in the model. Endoscopic subscore at screening was not prognostic of clinical remission at week 10 in cohort 1.
11 For our statistical analysis, nominal (nonmultiple test-corrected) P values were used to rank candidate genes associated with clinical remission.
11
Gene set enrichment analysis was used to characterize differences between clinical remitters and nonremitters in antiTNFÀnaïve patients treated with etrolizumab. This analysis was implemented using the GSEAlm Bioconductor package. 29 The Wald statistic generated by the DESeq2 algorithm was aggregated by summing the test statistics for a gene set and dividing by the square root of the gene-set size. This gene-set statistic was compared with a set of null statistics derived by permuting the clinical remission sample labels and recalculating the Wald statistic for differences between the permuted groups. An empirical P value was calculated by counting the number of permuted gene-set statistics that were more extreme (ie, further from 0) than the gene-set statistic calculated for the true sample labels.
Cell Sorting From Colonic Biopsies From Cohort 2
Colonic biopsies from cohort 2 were processed to a singlecell suspension. Mononuclear cells were extracted by incubation with 5 mM 1,4-dithiothreitol, followed by digestion with 1.5 mg/mL collagenase VIII and 0.05 mg/mL DNase I (Sigma, St Louis, MO for all reagents) then stained with Live/Dead stain (Life Technologies); CD45 PeCy5, TCRab PeCy7, CD8a allophycocyanin Cy7, CD4 Pacific Blue, aE integrin fluorescein isothiocyanate, b7 integrin allophycocyanin (all from Biolegend, London, UK), and CD8b phycoerythrin (Beckman Coulter).
þ T cells were sorted based on their expression of aE and b7 integrin directly into RLT buffer (Qiagen) containing b-mercaptoethanol. RNA was isolated using PicoPure RNA isolation kit (Life Technologies). Purity of the sorted populations was assessed to ensure samples had !85%
purity. Sorted T cells from inflamed biopsies were used for analysis in UC patients when available (11 of 13 patients).
Gene Expression Analysis by Quantitative Polymerase Chain Reaction
RNA isolated from RNAlater biopsies was reverse transcribed into complementary DNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies). Gene expression levels were measured by qPCR using the BioMark HD System (Fluidigm, South San Francisco, CA) with TaqMan PreAmp Master Mix (Life Technologies) and reagents (Fluidigm, South San Francisco, CA) using Taqman Gene Expression assays of respective genes (Life Technologies), according to manufacturer's instructions. Target gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) expression using the DCt method. Biopsies with missing aE (n ¼ 4) or GZMA (n ¼ 1) due to study logistical issues and data quality control were not included.
The top 45 differentially expressed genes identified from RNA sequencing analyses were annotated to leukocyte subsets based on their mean expression level in flow cytometry sortpurified peripheral immune cells. 27 qPCR analysis of baseline colonic GZMA or aE expression was used to categorize patients into GZMA high or aE high (greater than or equal to median) and GZMA low or aE low (less than median) subgroups.
Immunohistochemistry Quantification
Formalin-fixed tissue samples were obtained from both cohort 1 11 and cohort 2 patients. Geboes scoring and immunohistochemistry of aE were performed according to the protocol described previously 11 and adapted for immunofluorescence for co-staining. For dual immunofluorescence studies in cohort 2, anti-granzyme A polyclonal goat IgG (R&D Systems, Minneapolis, MN) was incubated for 60 minutes at 37 C. Antigoat Omnimap-HRP was used as detection, and 4 0 ,6-diamidino-2-phenylindole and hematoxylin II were used to counterstain the sections (Ventana Medical Systems, Inc, Tucson, AZ).
Statistical Analysis
Statistical testing was performed using the Mann-Whitney test, Wilcoxon matched-pairs signed rank test, or the Fisher's exact test, as appropriate, using Prism (GraphPad Software Inc., La Jolla, CA) or JMP (SAS Institute Inc, Cary, NC). No adjustments for multiple comparisons were performed. Subgroup analyses using the sample median cutoff were performed for granzyme A and aE. Positive predictive value was defined as biomarker high patients in remission/biomarker high patients and negative predictive value as biomarker low patients not in remission/biomarker low patients.
Results
Patient Demographics and Baseline Characteristics
The demographics and baseline characteristics of patients who participated in cohort 1 11 (n ¼ 110) and cohort 2 (n ¼ 21; unpublished data, 2014) have been detailed.
Enrichment of T-CellÀAssociated Genes in Baseline Biopsies of AntiÀTumor Necrosis Factor-Naïve Clinical Remitters Treated With Etrolizumab
In cohort 1 antiÀTNF-naïve patients, T-cellÀassociated genes were significantly enriched at baseline in clinical remitters compared with nonremitters (P < .05; Figure 1A) . Neutrophil-associated genes were significantly downregulated in clinical remitters (P < .01; Figure 1B ). Geneset enrichment analysis of DC-, monocyte-, and B-cellÀassociated genes showed no significant baseline differences between clinical remitters and nonremitters (Supplementary Figure 1) .
Clustering analysis of the top differentially expressed genes in antiÀTNF-naïve etrolizumab-treated patients showed that the main cluster of clinical remitters had up-regulation of genes with higher expression in sort-purified T cells (ITGAE, GZMA, GPR15, FGF9, PHF14, FAM125B, TMEM200A, TMIGD2, KLRB1, ECH1, FOXM1, and CPA2) and down-regulation of genes with higher expression in sort-purified neutrophils (VNN2, TMEM154, and LRRC4; Supplementary Figure 2) .
T Cells From Ulcerative Colitis Patients
In flow cytometryÀsorted T cells isolated from colonic biopsies from UC patients in cohort 2 ( Supplementary  Figure 3) , GZMA gene expression was significantly up-regulated in CD4 þ aE þ compared with CD4 þ aE À T cells (P < .0001; Figure 2A ); the level of granzyme A in CD4 þ aE þ cells was also significantly higher in UC patients compared with non-IBD controls (P < .05; Figure 2A ). GZMA gene expression was positively correlated with aE gene expres- Figure 2D ). Dual immunofluorescence analysis showed that granzyme A staining was limited to a subset of aE þ cells in colonic tissue, with the majority of aE þ granzyme A þ cells appearing to localize to the crypt epithelium ( Figure 2E ). These data suggest that aE þ cells may be a source of granzyme A in the colon.
Baseline Characteristics and Enrichment of Clinical Remission and Mucosal Healing Using ITGAE and GZMA
Both aE integrin (ITGAE) and granzyme A (GZMA) were identified by differential gene expression analysis. Enrichment of clinical remission ( Figure 3A ) and mucosal healing ( Figure 3B ) in response to etrolizumab was observed in cohort 1 patients with high baseline colonic biopsy GZMA gene expression (clinical remission: all patients (positive predictive value/negative predictive value): 100 mg, 41%/94%; 300 mg þ LD, 18%/95%; antiÀTNF-naïve (positive predictive value/negative predictive value): 100 mg, Figure 1 . Differences in baseline colonic biopsy gene expression between clinical remitters and nonremitters treated with etrolizumab. Distribution of curated (A) T-cellÀ and (B) neutrophil-associated genes in baseline colonic biopsies of antiÀTNF-naïve etrolizumab-treated patients. P value was empirically calculated by counting the number of permuted geneset statistics that were more extreme than the gene-set statistic calculated for the true sample labels. X-axis represents clinical remitter to nonremitter gene-set statistic.
75%/88%; 300 mg þ LD, 50%/100%). Enrichment of clinical remission in aE high patients in cohort 1 has been detailed. 11 Enrichment of mucosal healing was observed in aE high patients in cohort 1 in response to 100-mg etrolizumab (Supplementary Figure 5) . The combination of ITGAE and GZMA, while resulting in small patient subsets, showed a further enrichment of clinical remission (Supplementary Table 2 ). Baseline clinical characteristics were balanced across treatment groups in both the ITGAE and GZMA biomarker subgroups, with the exception of older age and lower immunosuppressant use in the GZMA high group compared with the GZMA low group (Supplementary Table 2 ). There was no significant difference in the distribution of baseline GZMA or aE 11 by previous anti-TNF use (Supplementary Figure 6) . Table 3) .
A subset of patients had biopsies available for histologic analysis.
11 aE low patients had higher modified Geboes scores 30 at baseline than aE high patients (mean ± SD, 2.3 ± 0.8 and 1.7 ± 0.9, respectively; P < .01); no significant difference was observed between GZMA subgroups (Supplementary Table 2 ).
Post-Treatment Effects of Etrolizumab in Biomarker high and Biomarker low Patients
At baseline, the number of epithelial-associated aE þ cells was significantly higher in both aE high and GZMA high patients than aE low and GZMA low patients, respectively (median ± median absolute deviation, 5.6 ± 2.6 in both aE high and GZMA high vs 2.6 ± 1.6 and 2.9 ± 1.7 in aE low and GZMA low patients respectively; P < .01 both; Figure 4A ). All epithelialassociated aE þ cells were included in this analysis, as no costains (eg, CD3 or CD4) were used. Etrolizumab treatment significantly reduced the number of epithelial-associated aE þ cells at week 10 in aE high (median ± median absolute deviation, 33% ± 25%; P < .05) and GZMA high patients (median ± median absolute deviation,: 36% ± 22%; P < .01), while there was no significant reduction in epithelial-associated aE þ cells in aE low and GZMA low patients post-etrolizumab treatment ( Figure 4B ). Etrolizumab treatment also significantly changed gene expression in GZMA high etrolizumab-treated patients relative to placebo. T-cellÀassociated genes (aE, granzyme A, and granzyme B; P < .05; Figure 5A ) and cytokines and chemokines (interleukin 17F, interleukin 8, CCL4, and CXCL1; P < .05; Figure 5B ) were reduced in expression at week 10 in GZMA high etrolizumab-treated patients compared with placebo. There was no significant difference in these genes between placebo and etrolizumab-treated patients in the GZMA low subgroup at week 10. GZMA high patients had higher expression of aE, granzyme B, and CCL5 and lower expression of CXCL1 at baseline than GZMA low patients (Supplementary Figure 7A ; P < .05ÀP < .001). Only CCL5 was significantly decreased at week 10 in aE high etrolizumab-treated patients compared with placebo (P < .05; Supplementary Figure 8) ; CCL5 was significantly higher in aE high patients than aE low patients at baseline (P < .05; Supplementary Figure 7B) . þ aE þ T cells from UC patients in cohort 2. In cohort 1, GZMA gene expression was significantly correlated with (C) aE gene expression (dotted lines indicate qPCR median cutoff) and (D) the number of aE þ cells in the epithelium and LP in colonic biopsies. (E) Representative immunofluorescence co-staining of granzyme A and aE in a colonic biopsy sample from cohort 2. *P < .05; ****P < .0001.
Differences in histologic changes were observed at week 10 by biomarker subgroups. The modified Geboes score was significantly higher at baseline in aE low patients and was significantly reduced at week 10 among etrolizumab-treated patients compared with those treated with placebo (P < .01; Supplementary Figure 9 ). The modified Geboes score was significantly decreased at week 10 in etrolizumab-treated GZMA high patients, but not GZMA low patients, compared with placebo (P < .05; Supplementary Figure 9 ). There were no apparent changes in the placebo arm in either biomarker subgroup.
Discussion
Drug therapies, such as etrolizumab, that selectively block leukocyte trafficking are emerging treatment options for UC. 12 Etrolizumab has demonstrated clinical efficacy in a phase 2 study of moderate to severely active UC, and a subset of patients with high colonic aE expression showed even greater benefits. 11 Identification of additional predictive biomarkers for response to treatment with etrolizumab could improve the efficiency of therapy for moderate to severely active UC through a personalized medicine approach. We evaluated gene expression post-hoc in baseline biopsies from antiÀTNF-naïve UC patients treated with etrolizumab and found higher baseline expression of T-cellÀassociated genes, including aE integrin and granzyme A, in clinical remitters. aE gene expression was found to correlate with granzyme A gene expression, was significantly higher in CD4 þ aE þ cells than CD4 þ aE À cells sorted from UC patients, and a subset of aE þ cells were found to co-express granzyme A in colonic tissue. Enrichment of clinical remission and mucosal healing was observed in both aE high , 11 and GZMA high patients. Some differences in baseline characteristics between biomarker subgroups were observed, including lower endoscopy and histologic scores in aE high patients, but the clinical relevance is unclear. However, neither the endoscopy score nor histologic score at baseline were predictive of remission in response to etrolizumab at week 10 in cohort 1. Both aE high and GZMA high patients had higher numbers of aE þ cells in crypt epithelium at baseline and showed decreased aE þ crypt-associated cells after etrolizumab treatment compared with placebo. In line with the previously reported reduction in gene expression in etrolizumab remitters, 11 we found a significant decrease in colonic biopsy gene expression of T-cellÀassociated genes and inflammatory cytokines and chemokines in GZMA high patients treated with etrolizumab relative to placebo. Both of these potential predictive biomarkers will be tested prospectively in phase 3 studies.
In this study, increased expression of T-cellÀassociated genes was found in baseline biopsies of antiÀTNF-naïve patients who achieved clinical remission in response to etrolizumab. In contrast, no difference in immune cell types was observed in TNF-inadequate responder patients in comparison to antiÀTNF-naïve patients using the same geneset analysis in baseline biopsies (data not shown). Higher rates of efficacy were observed in this study in antiÀTNF-naïve patients and the 100-mg dose group, which could be due to differential effects of etrolizumab on particular cell types or other reasons related to study powering or demographic differences, as discussed elsewhere. 11 The specificity and exclusivity of the gene lists have been discussed. 27 These cell-associated gene lists were generated based on relatively exclusive expression of genes in a particular cell type compared with other cell types. 27 Due to the small number of NK cellÀspecific genes and the fact that many of these genes were below the minimum expression threshold used in the analysis, our findings on NK gene-set enrichment were inconclusive (data not shown). Minor cell populations not included in sorted gene sets, 27 such as innate lymphoid cells and NKT cells, may also express some of the genes identified as exclusively expressed.
Higher baseline levels of 2 biomarkers found predominantly on T cells, aE integrin and granzyme A, enriched for clinical remission after etrolizumab treatment. Granzyme A co-localized with aE expression in colonic biopsies, suggesting that aE þ cells could be a key source of granzyme A in the colon. Granzyme A, a serine protease present in activated and cytotoxic NK, NKT, and T cells, 31 lacks direct cytotoxic activity at low concentrations, but has been implicated in the release of inflammatory cytokines, such as interleukin 1b and TNFa. 32 Granzyme A has been shown to induce cleavage of extracellular matrix components, such as fibronectin and proteoglycan, 33 to potentially facilitate cell migration. Emergence of granzyme AÀexpressing human immunodeficiency virusÀspecific T cells has been associated with slower human immunodeficiency virus disease progression. 34 Although further studies will be required to evaluate the role of aE þ granzyme A þ cells in intestinal mucosa, the known functions are consistent with those of an effector cell phenotype.
Differences in baseline biopsy gene expression were observed based on biomarker status. Heterogeneity was observed in baseline measurements and individual patient data were shown to highlight variability where possible. Small numbers of samples in placebo groups should also be noted. Baseline CCL5 was significantly higher in the aE high subgroup than the aE low subgroup, indicating that the aE high environment may be associated with increased T-cell infiltration. GZMA high patients had significantly increased CCL5, but decreased CXCL1, at baseline than GZMA low patients.
CCL5 is a chemoattractant for peripheral memory T-helper cells, while CXCL1 is a chemoattractant for neutrophils. GZMA high patients may have increased recruitment of activated T cells and altered neutrophil infiltration. These findings support the benefits of using both of these biomarkers for the identification of UC patients likely to respond to etrolizumab therapy. Although aE b7 þ cells also expressed a4, 10 post-hoc analysis suggests that a4 is a pharmacodynamic 10 but not a predictive biomarker of etrolizumab (data not shown). The value of aE and GZMA as predictive biomarkers could be due to their specificity as surrogate markers of a subset of effector T cells that are impacted by etrolizumab.
Changes in gene expression post treatment were also different based on biomarker status, with significant effects observed when substratifying patients based on GZMA expression, supporting the idea that GZMA may be a promising biomarker for etrolizumab response. Granzyme A marks a subpopulation of aE þ T cells in gut mucosa, and we Figure 4 . Effect of etrolizumab on epithelial crypt-associated aE þ cells by biomarker stratification. Epithelial crypt-associated aE þ cells were counted before and after treatment with etrolizumab or placebo in cohort 1. (A) Baseline distribution of epithelial crypt-associated aE þ cells in GZMA high or aE high (greater than or equal to median) or GZMA low or aE low (less than median) patients where baseline colonic biopsy qPCR median value was used to categorize patients. (B) Change in epithelial cryptassociated aEþ cells in GZMA high or aE high and GZMA low or aE low patients after treatment with etrolizumab (combined dose groups) or placebo. *P < .05; **P < .01. Scr, screening.
observed a positive correlation between GZMA and aE gene expression in colonic biopsies as well as in sorted CD4
þ aE þ cells. In sorted CD4 þ aE þ cells, the expression of GZMA was significantly up-regulated in UC patients relative to controls.
These biomarkers were also positively correlated with effector molecules, such as Fas ligand and perforin, suggesting that these CD4 þ cells might have acquired effector phenotypes of cytolytic lymphocytes (CD4 þ cytotoxic T Figure 5 . 39 Recent work supports that this cell population may also play a role in UC, where higher expression of inflammatory cytokines are observed in CD4 þ aE þ T cells in inflamed biopsies from UC patients compared with non-IBD controls (unpublished data, 2014). The enhanced benefits of etrolizumab on clinical remission and mucosal healing in patients with high GZMA and aE gene expression in baseline colonic biopsies support the hypothesis that increased activation and retention of T cells in the gut may play a crucial role in the pathobiology of UC. It should be noted that the sample size in these studies is small and further analysis will be required to test this hypothesis. In addition, the specificity of these observations for etrolizumab therapy in comparison with other therapies will need to be evaluated.
We observed a greater histologic improvement from baseline in etrolizumab-treated aE low patients, suggesting increased benefits in microscopic healing in these patients than aE high patients. Enrichment of clinical benefit was observed in aE high patients, but the lower histologic grade at baseline in aE high patients might have led to less sensitivity for histologic changes after treatment. Histologic improvement did not translate to clinical benefits in aE low patients within the 10-week trial period of cohort 1, but patients did achieve a histologic score similar to baseline levels of aE high patients by the end of the study, and a longer treatment period may be needed to assess the clinical benefits after histologic healing. Compared with aE subgroups, GZMA subgroups had balanced histologic and endoscopic scores at baseline, but enriched clinical remission was only observed in GZMA high patients. Immunohistochemistry assessment of granzyme A expression in a subset of aE þ cells may be equally important for patient identification. Epithelial erosion or loss of intestinal epithelial cells that express E-cadherin in the setting of active UC could further reduce the anchoring of aE þ cells in the epithelium and therefore the quantification of aE transcripts by qPCR. Geboes erosion subscore, but not crypt destruction or the presence of neutrophils in the epithelium (data not shown), was higher in aE low patients than aE high patients at baseline, suggesting that aE low patients may have increased inflammation involving erosion of the epithelium without other differences in active disease measured by histology. However, histologic scores were not different between GZMA high and GZMA low patients. The absence of baseline differences between GZMA subgroups suggests that granzyme A þ cells may be less affected by epithelial loss and therefore be a more robust and stable biomarker without the confounding effects of epithelial erosions that may impact aE levels.
The potential predictive biomarker profile identified in this study is the first of its kind in a moderate to severely active UC patient population and could pave the way for a personalized medicine approach to therapeutic decision making. The pathobiology of IBD is complex, and customizing therapy to a patient's predictive biomarker profile will be important in creating optimal therapeutic responses and tailoring therapy for patients. Larger studies are underway to validate the findings of this study, with prospective analyses of baseline biomarker levels and exploration of clinically relevant biomarker cutoffs to test for enriched response to etrolizumab.
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Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at http://dx.doi.org/10.1053/ j.gastro.2015.10.041. = Supplementary Figure 7 . Distribution of baseline gene expression of aE, granzyme B, CXCL1, and CCL5 by biomarker status and treatment group. Baseline colonic biopsy gene expression was assessed by qPCR in cohort 1. Baseline colonic biopsy qPCR median value was used as cutoff to categorize patients as granzyme A high or aE high (greater than or equal to median) or granzyme A low or aE low (less than median). (A) aE, granzyme B, CCL5, and CXCL1 gene expression relative to glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (GAPDH) expression in baseline colonic biopsy by granzyme A status. (B) CCL5 expression relative to GAPDH in baseline colonic biopsy by aE status. NS, not significant; *P < .05; **P < .01; ***P < .001. Supplementary Figure 8 . Effect of etrolizumab on CCL5 colonic biopsy gene expression by aE stratification. Colonic biopsy gene expression was assessed by qPCR before and after treatment with etrolizumab or placebo in cohort 1. Baseline colonic biopsy qPCR median value was used as cutoff to categorize patients as aE high (greater than or equal to median) or aE low (less than median). Decreased CCL5 expression in colonic biopsy in aE high patients treated with etrolizumab, but not aE low patients relative to placebo was observed. Data presented as fold (2 ÀDDCt ) group median ± median absolute deviation. P values correspond to the comparison between etrolizumab and placebo. *P < .05 (vs placebo). SCR, screening. NOTE. Genes used for each of the leukocyte subsets in the gene-set enrichment analysis are listed.
